Category: Nevin Manimala

Neuropsychopharmacol Rep. 2025 Mar;45(1):e70002. doi: 10.1002/npr2.70002.

ABSTRACT

BACKGROUND: Alcohol use disorder (AUD) is characterized by severe dependence on alcohol, poor impulse control, and heightened attention to alcohol-related cues. Attention bias modification (ABM) retrains individuals to distract attention from alcohol-related cues. This study investigates the effect of combining ABM with cognitive behavioral therapy (CBT) to reduce relapse risk and cravings in male patients with AUD.

METHODS: A quasi-randomized controlled trial was conducted among male inpatients diagnosed with AUD. Participants were divided into an intervention group receiving ABM in addition to CBT and a control group receiving CBT with a placebo intervention. The primary outcomes-risk of relapse and craving levels-were measured using the Alcohol Relapse Risk Scale (ARRS) and a visual analog scale (VAS), respectively. Participants underwent weekly sessions over 6 weeks, and outcomes were analyzed using generalized linear models (GLMs).

RESULTS: The analysis did not reveal significant interactions between the intervention group and time for ARRS scores and craving levels. Both groups experienced a reduction in relapse risk and cravings. However, there was no significant difference between the ABM + CBT and CBT-only groups.

CONCLUSIONS: Although the combined ABM and CBT intervention did not result in statistically significant reductions in relapse risk and cravings compared to CBT alone, the overall reduction in these outcomes in both groups highlights the effectiveness of CBT in treating AUD. Future studies should use naturalistic settings and tailor the intervention to individual cognitive profiles.

PMID:39907051 | DOI:10.1002/npr2.70002

J Am Geriatr Soc. 2025 Feb 5. doi: 10.1111/jgs.19386. Online ahead of print.

ABSTRACT

OBJECTIVE: The primary objective of this study was to assess the prescribing patterns of long acting injectable (LAI) antipsychotics in an older adult population. Secondary objectives were to determine if there were differences in treatment discontinuation rates between different LAI agents and race/ethnicity.

METHODS: Merative MarketScan Multi-State Medicaid Databases (2017-2021) were used to identify patients 65 years or older who were prescribed a LAI antipsychotic. Pharmacy claims for LAI antipsychotics were referenced via National Drug Code (NDC) by brand/generic name and dose. International Classification of Diseases, 10th edition (ICD-10) codes were used to identify older adults diagnosed with schizophrenia, schizotypal or schizoaffective disorders. Those with dementia or related disorders were censored. Conditional associations between race/ethnicity and generation of LAI antipsychotics were investigated using logistic regression controlling for age, sex, and health plan. Cox proportional hazard regression was used to compare the distribution of time until treatment discontinuation among older adults across LAI antipsychotics.

RESULTS: A total of 526 older adults (59% female) with an average age of 70.4 ± 5.5 years met inclusion for analysis. The most commonly used LAI antipsychotics included paliperidone palmitate-1 month formulation (~35%), haloperidol decanoate (~24%), and risperidone microspheres (~15%). Overall, approximately 32% received LAI first-generation antipsychotics and 68% received LAI second generation antipsychotics. Blacks (n = 204) received LAI first-generation antipsychotics more often than Whites (n = 283); (OR: 1.74, 95% [1.18, 2.56], p < 0.01). When controlling for age, sex, and race/ethnicity, LAI first-generation antipsychotics showed earlier discontinuation rates compared to LAI second-generation antipsychotics (HR: 2.12, 95% CI [1.45, 3.10], p < 0.001).

CONCLUSIONS: LAI first-generation antipsychotics showed treatment discontinuation significantly earlier compared to LAI second-generation antipsychotics. Furthermore, Blacks were prescribed LAI first-generation antipsychotics at a higher rate than Whites, which may contribute to poorer health outcomes. Futures studies are needed to establish a causal relationship.

PMID:39907048 | DOI:10.1111/jgs.19386

Neuropsychopharmacol Rep. 2025 Mar;45(1):e70001. doi: 10.1002/npr2.70001.

ABSTRACT

AIMS: Alzheimer’s disease (AD) is a leading cause of dementia, with increasing prevalence. Mutations in genes like MAPT, PSEN1, and PSEN2 are risk factors, leading to the development of several AD model mice. Recent hypotheses suggest AD brain pathology involves abnormal neurodevelopment, decreased pH, and neural hyperexcitation. However, it remains unclear to what extent these pathologies are reflected in the gene expression changes of AD models. This study aims to compare gene expression patterns in the brains of multiple AD model mice with those related to these three factors, evaluating the extent of overlap.

METHODS: We conducted a comprehensive search of public databases, collecting 20 gene expression datasets from the hippocampus of AD model mice. These datasets were compared with gene sets related to hippocampal maturation, brain pH, and neural hyperexcitation to statistically assess overlap. Pathway enrichment analysis explored the biological relevance of these gene expression changes.

RESULTS: The extent of overlap with maturity-, pH-, and hyperexcitation-associated genes varied across AD models, showing significant correlations between lower maturity, lower pH, and increased neural hyperexcitation. In MAPT mutant and APP+PSEN1 homozygous transgenic mice, these signatures became more pronounced with age. Pathway meta-analysis revealed that genes associated with maturity, pH, and hyperexcitation in AD models are involved in synaptic and channel functions, as well as inflammatory responses, consistent with previous studies.

CONCLUSION: These findings suggest that pathophysiological changes related to maturity, pH, and neural hyperexcitation play varying roles across individual AD model mice. Our recent study found a negative correlation between disease progression and actual pH levels in human AD patients. Considering the results presented in this study, maturity and neural hyperexcitation, which are correlated with pH, may also be linked to disease progression. Thus, gene expression changes in these factors could be useful markers for assessing the pathology in AD models.

PMID:39907034 | DOI:10.1002/npr2.70001

Afr J Reprod Health. 2025 Jan 31;29(1):153-159. doi: 10.29063/ajrh2025/v29i1.16.

ABSTRACT

This study investigates the safety of non-surgical periodontal treatment during long-term low-dose aspirin therapy in patients with chronic periodontitis and gynaecological conditions, focusing on bleeding risk and coagulation function. Patients received low-dose aspirin (100 mg/d) and were divided into a medication continuation group (observation) and a cessation group (control), with 41 patients each. Key periodontal parameters (plaque index, probing depth, attachment loss) and coagulation indices (activated partial thromboplastin time, prothrombin time, thrombin time, prothrombin activity) were assessed post-treatment. Results showed no significant difference in coagulation indices and bleeding scores between the groups (P > 0.05). Grade 3 bleeding incidents were slightly higher in the observation group but not statistically significant. The observation group’s maximum platelet aggregation rate was significantly lower (P < 0.0001), with no significant differences in activated partial thromboplastin time, prothrombin time, thrombin time, or prothrombin activity. The findings suggest that non-surgical periodontal treatment is safe for these patients under long-term low-dose aspirin therapy, with limited increased bleeding risk.

PMID:39907007 | DOI:10.29063/ajrh2025/v29i1.16

J Clin Sleep Med. 2025 Feb 5. doi: 10.5664/jcsm.11576. Online ahead of print.

ABSTRACT

STUDY OBJECTIVES: We propose to identify different sleep phenotypes in infancy, relying on auto-videosomnography metrics.

METHODS: In this cross-sectional study, objective infant sleep metrics of six hundred twenty-three infants aged 9 to 13 months, recruited among users of Nanit baby-monitor in the United States, were obtained from Nanit auto-videosomnography (1 week of data averaged) in the child’s natural sleep environment. A cluster analysis was conducted to group infants based on sleep metrics.

RESULTS: Three reproducible and stable sleep phenotypes were identified: Long Sleepers (n.338), Interrupted Sleepers (n.130) and Short Sleepers (n.155). All sleep metrics were statistically significant different in the three groups. Long Sleepers had longer nighttime sleep duration than Interrupted and Short Sleepers. Interrupted Sleepers presented more awakenings than Short and Long Sleepers, and similarly more parental interventions. Short Sleepers presented later bedtimes and earlier wake up times when compared with Long and Interrupted Sleepers. Nighttime sleep efficiency was better in Long Sleepers than in Interrupted and Short Sleepers, but Short Sleepers presented better sleep efficiency than Interrupted Sleepers.

CONCLUSIONS: Cluster analysis based on objective sleep metrics offers a novel multidimensional approach for the early identification of infants’ sleep patterns. Phenotyping sleep patterns is extremely important in identifying the risk for developing neurobehavioral disorders since night wakings and reduced sleep duration in infancy might be predictive of the development of emotional and behavioral problems later in childhood.

PMID:39906982 | DOI:10.5664/jcsm.11576

Afr J Reprod Health. 2025 Jan 31;29(1):144-152. doi: 10.29063/ajrh2025/v29i1.15.

ABSTRACT

This study aims to determine the Turkish validity and reliability of the questionnaire for the detection of invisible violence against women. This methodological study was conducted online with 221 single women with an intimate partner and 277 married women. The scale was confirmed that the 23-item scale had 5 sub-scales. Fit indices were found χ2/sd=2.202, TLI=.900, RMSEA=.074, SRMR =.0571, AGFI=.800, GFI=.850, IFI=.903, CFI=.902 and df= 214 in single women who had an intimate partner. Fit indices were found χ2/sd=2.212, TLI=.901, RMSEA=.066, SRMR=.0582, AGFI=.827, GFI=.864, IFI=.916, CFI=.915 and df=216 in married women. The scale Cronbach’s alpha coefficient was found to be 0.93 for the whole scale. And also the reliability of scale showed that it has excellent Cronbach’s alpha coefficient of 0.84, 0.83, 0.86, 0.74 and 0.72 for the subscales of crisis, utilitarian, coercive, ambivalent and benevolent sexist behaviors respectively. The Turkish version of the questionnaire for the detection of invisible violence against women is a valid and reliable measurement tool for married/single women who have an intimate partner.

PMID:39906976 | DOI:10.29063/ajrh2025/v29i1.15

Hum Vaccin Immunother. 2025 Dec;21(1):2459459. doi: 10.1080/21645515.2025.2459459. Epub 2025 Feb 5.

ABSTRACT

Vaccination is the most effective measure to prevent Chlamydia infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective Chlamydia vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding Chlamydia vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. Vaccine has published the most literature on Chlamydia vaccines. Only scholars from 39 countries/regions have been engaged in studying Chlamydia vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.

PMID:39906958 | DOI:10.1080/21645515.2025.2459459

CPT Pharmacometrics Syst Pharmacol. 2025 Feb 5. doi: 10.1002/psp4.13310. Online ahead of print.

ABSTRACT

IMscin001 is a two-part dose-finding (Phase Ib) and -confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The objectives of the current analyses were to characterize the population pharmacokinetics (popPK) of atezolizumab and to determine the relationship between atezolizumab exposure and safety and efficacy endpoints in IMscin001. A previously validated IV popPK model was extended to add SC absorption parameters using SC and IV data from Phase Ib and Phase III of IMscin001 (N = 435), and covariate effects were investigated on the SC absorption parameters. The exposure-response (ER) investigation was performed using SC data following 1875 mg every three weeks (q3w) administration in the Phase III portion of IMscin001 (N = 246). The clinical endpoints were objective response rate, progression-free survival, or overall survival for efficacy, serious adverse events, special interest adverse events, Grades 3-5 adverse events, infusion-related reaction, or injection site reactions for safety. Atezolizumab SC absorption was characterized by a first-order absorption with a bioavailability of 71.8% and an absorption rate constant of 0.304 day^-1. The extended popPK model was adequate to predict atezolizumab PK after IV and SC administrations and to predict individual exposure metrics. For all efficacy and safety endpoints, atezolizumab exposure was not statistically significant (p-value > 0.05) in the ER models. The non-inferior popPK exposure and flat ER results supported atezolizumab SC dose at 1875 mg q3w.

PMID:39906948 | DOI:10.1002/psp4.13310

Histol Histopathol. 2025 Jan 28:18880. doi: 10.14670/HH-18-880. Online ahead of print.

ABSTRACT

BACKGROUND: Breast cancer is the most prominent cancer among women worldwide, with a two-fold incidence in China compared to the worldwide incidence. ALDH1A1, catalyzing the oxidation of intracellular aldehydes and converting retinol into retinoic acid, serves as a biomarker of early stem cell differentiation. Ki67 levels are prognostic or residual risk biomarkers after primary therapy and can predict the effects of systemic therapies or monitor patients for sustained response or resistance to the administered therapies. This study aimed to investigate the correlation between ALDH1A1 and Ki67 expression and clinicopathological parameters among women with breast cancer.

METHODS: Breast cancer tissue specimens were obtained from the Department of Pathology at the First Hospital of Qiqihar. Indirect fluorescent immunostaining was used to assess the expression of ALDH1A1 and Ki67 in breast cancer and healthy tissues. Associations between ALDH1A1 and Ki67 expression and clinicopathological parameters of breast cancer were evaluated using the chi-square test. A p-value less than 0.05 was considered statistically significant. The correlation between ALDH1A1 and Ki67 expression was assessed using Spearman’s rank correlation analysis.

RESULTS: ALDH1A1 and Ki67 were upregulated in breast cancer tissue compared with normal breast tissue (p<0.05). Furthermore, ALDH1A1 expression was further upregulated with an advancement in breast cancer grade, i.e., ALDH1A1 expression levels were higher in patients with stage III/IV breast cancer than in those with stage I/II breast cancer. Furthermore, ALDH1A1 and Ki67 were upregulated in the presence of lymphatic metastasis.

CONCLUSION: ALDH1A1 may be considered a pathognomonic marker for breast cancer. ALDH1A1 and Ki67 expression are significantly positively correlated in women with breast cancer.

PMID:39906934 | DOI:10.14670/HH-18-880

Plant Genome. 2025 Mar;18(1):e20556. doi: 10.1002/tpg2.20556.

ABSTRACT

Plant varieties must satisfy distinctness, uniformity, and stability (DUS) requirements for registration. Morphophysiological trait-based distinctness may be challenging for cultivars of major perennial forages. Our study focused on alfalfa (Medicago sativa L. subsp. sativa) with the aims of (a) comparing morphophysiological distinctness with molecular distinctness based on genotyping-by-sequencing (GBS) or the alfalfa DArTag panel, envisaging different statistical criteria for molecular distinctness, and (b) assessing the consistency of morphophysiological and molecular cultivar diversity. The 18 most grown Italian varieties were jointly reevaluated morphophysiologically and were characterized molecularly using three bulked DNA samples of 200 independent genotypes per cultivar. Morphophysiological distinctness was limited by correlations between traits and resulted in 39 non-distinct cultivars in 153 paired comparisons and three cultivars distinct from any other. Best configurations for molecular distinctness featured about 10-fold more polymorphic markers and 10-fold lower average read depth per marker for GBS compared to DArTag. DArTag markers allowed for somewhat better variety distinction than GBS. They reduced to 11 the non-distinct cultivars in paired comparisons and increased to 11 the completely distinct cultivars, based on a principal components analysis of allele frequencies followed by analyses of variance on cultivar principal component scores. This criterion achieved greater variety distinctness than cluster analysis with bootstrap values, discriminant analysis, or analysis of molecular variance. Morphophysiologically distinct cultivars were generally distinct molecularly, but not the reverse. Mantel’s test revealed a modest consistency across morphophysiological and DArTag (r = 0.39) or GBS-based (r = 0.46) measures of cultivar Euclidean distance. Our results and other considerations strongly encourage the adoption of molecular distinctness for alfalfa DUS.

PMID:39906928 | DOI:10.1002/tpg2.20556